Adenoviral vector with shield and adapter increases tumor specificity and escapes liver and immune control

[1]  L. Seymour,et al.  Oncolytic adenovirus expressing bispecific antibody targets T‐cell cytotoxicity in cancer biopsies , 2017, EMBO molecular medicine.

[2]  B. Champion,et al.  Development of a versatile oncolytic virus platform for local intra-tumoural expression of therapeutic transgenes , 2017, PloS one.

[3]  S. Nicklin,et al.  Defining a Novel Role for the Coxsackievirus and Adenovirus Receptor in Human Adenovirus Serotype 5 Transduction In Vitro in the Presence of Mouse Serum , 2017, Journal of Virology.

[4]  Bruce F. Smith,et al.  Cell-Surface Integrins and CAR Are Both Essential for Adenovirus Type 5 Transduction of Canine Cells of Lymphocytic Origin , 2017, PloS one.

[5]  T. Simmet,et al.  Substitution of blood coagulation factor X-binding to Ad5 by position-specific PEGylation: Preventing vector clearance and preserving infectivity. , 2016, Journal of controlled release : official journal of the Controlled Release Society.

[6]  C. Lubich,et al.  The Mystery of Antibodies Against Polyethylene Glycol (PEG) - What do we Know? , 2016, Pharmaceutical Research.

[7]  M. Havenga,et al.  Development of Novel Adenoviral Vectors to Overcome Challenges Observed With HAdV-5–based Constructs , 2015, Molecular therapy : the journal of the American Society of Gene Therapy.

[8]  Luigi Naldini,et al.  Gene therapy returns to centre stage , 2015, Nature.

[9]  M. Wenk,et al.  Co-option of Membrane Wounding Enables Virus Penetration into Cells. , 2015, Cell host & microbe.

[10]  Joung-Woo Choi,et al.  pH-sensitive oncolytic adenovirus hybrid targeting acidic tumor microenvironment and angiogenesis. , 2015, Journal of controlled release : official journal of the Controlled Release Society.

[11]  A. Kamen,et al.  Large-scale adenovirus and poxvirus-vectored vaccine manufacturing to enable clinical trials. , 2015, Biotechnology journal.

[12]  Taco G. Uil,et al.  Manipulating Adenovirus Hexon Hypervariable Loops Dictates Immune Neutralisation and Coagulation Factor X-dependent Cell Interaction In Vitro and In Vivo , 2015, PLoS pathogens.

[13]  L. Scott.  Alipogene Tiparvovec: A Review of Its Use in Adults with Familial Lipoprotein Lipase Deficiency , 2015, Drugs.

[14]  Jie Tian,et al.  Impact of Natural IgM Concentration on Gene Therapy with Adenovirus Type 5 Vectors , 2014, Journal of Virology.

[15]  K. Uchida.  Natural antibodies as a sensor of electronegative damage-associated molecular patterns (DAMPs). , 2014, Free radical biology & medicine.

[16]  S. W. Kim,et al.  Utilizing adenovirus vectors for gene delivery in cancer , 2014, Expert opinion on drug delivery.

[17]  U. Greber,et al.  Innate immunity to adenovirus. , 2014, Human gene therapy.

[18]  K. Ulbrich,et al.  Traceless Bioresponsive Shielding of Adenovirus Hexon with HPMA Copolymers Maintains Transduction Capacity In Vitro and In Vivo , 2014, PloS one.

[19]  Samuel Kilcher,et al.  Tracking viral genomes in host cells at single-molecule resolution. , 2013, Cell host & microbe.

[20]  U. Greber,et al.  A Direct and Versatile Assay Measuring Membrane Penetration of Adenovirus in Single Cells , 2013, Journal of Virology.

[21]  Jie Tian,et al.  Coagulation factor X shields adenovirus type 5 from attack by natural antibodies and complement , 2013, Nature Medicine.

[22]  A. Gounder,et al.  Directed Evolution of Mutator Adenoviruses Resistant to Antibody Neutralization , 2013, Journal of Virology.

[23]  A. Plückthun,et al.  Development of a generic adenovirus delivery system based on structure-guided design of bispecific trimeric DARPin adapters , 2013, Proceedings of the National Academy of Sciences.

[24]  U. Greber,et al.  Uncoating of non-enveloped viruses. , 2013, Current opinion in virology.

[25]  Jo Wixon,et al.  Gene therapy clinical trials worldwide to 2012 – an update , 2013, The journal of gene medicine.

[26]  James W. MacDonald,et al.  Coagulation Factor X Activates Innate Immunity to Human Species C Adenovirus , 2012, Science.

[27]  G. Nemerow,et al.  Identification of Adenovirus Serotype 5 Hexon Regions That Interact with Scavenger Receptors , 2011, Journal of Virology.

[28]  J. Trowsdale,et al.  Intracellular antibody‐mediated immunity and the role of TRIM21 , 2011, BioEssays : news and reviews in molecular, cellular and developmental biology.

[29]  U. Greber,et al.  Drifting motions of the adenovirus receptor CAR and immobile integrins initiate virus uncoating and membrane lytic protein exposure. , 2011, Cell host & microbe.

[30]  U. Greber,et al.  Chemotactic antiviral cytokines promote infectious apical entry of human adenovirus into polarized epithelial cells , 2011, Nature communications.

[31]  L. James,et al.  Antibodies mediate intracellular immunity through tripartite motif-containing 21 (TRIM21) , 2010, Proceedings of the National Academy of Sciences.

[32]  V. Kähäri,et al.  Requirements for Receptor Engagement during Infection by Adenovirus Complexed with Blood Coagulation Factor X , 2010, PLoS pathogens.

[33]  M. Barry,et al.  Targeting adenoviruses with factor x-single-chain antibody fusion proteins. , 2010, Human gene therapy.

[34]  K. Breckpot,et al.  Lentiviral Vectors in Gene Therapy: Their Current Status and Future Potential , 2010, Archivum Immunologiae et Therapiae Experimentalis.

[35]  K. Harrington,et al.  Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  A. Ristimäki,et al.  Systemic adenoviral gene delivery to orthotopic murine breast tumors with ablation of coagulation factors, thrombocytes and Kupffer cells , 2009, The journal of gene medicine.

[37]  Michael M. Schmidt,et al.  A modeling analysis of the effects of molecular size and binding affinity on tumor targeting , 2009, Molecular Cancer Therapeutics.

[38]  D. Bhella,et al.  Identification of coagulation factor (F)X binding sites on the adenovirus serotype 5 hexon: effect of mutagenesis on FX interactions and gene transfer. , 2009, Blood.

[39]  K. Ulbrich,et al.  Coating of adenovirus type 5 with polymers containing quaternary amines prevents binding to blood components. , 2009, Journal of controlled release : official journal of the Controlled Release Society.

[40]  Jie Tian,et al.  Clearance of Adenovirus by Kupffer Cells Is Mediated by Scavenger Receptors, Natural Antibodies, and Complement , 2008, Journal of Virology.

[41]  C. Napoli,et al.  Adenovirus Serotype 5 Hexon Mediates Liver Gene Transfer , 2008, Cell.

[42]  B. Movsas,et al.  Prostate cancer gene therapy clinical trials. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[43]  S. William,et al.  Adenovirus Methods and Protocols , 2006, Methods in Molecular Medicine.

[44]  D. Sze,et al.  Minimal hepatic toxicity of Onyx-015: spatial restriction of coxsackie-adenoviral receptor in normal liver , 2006, Cancer Gene Therapy.

[45]  A. Parker,et al.  Multiple vitamin K-dependent coagulation zymogens promote adenovirus-mediated gene delivery to hepatocytes. , 2006, Blood.

[46]  P. Jeena,et al.  Age Dependence of Adenovirus-Specific Neutralizing Antibody Titers in Individuals from Sub-Saharan Africa , 2006, Journal of Clinical Microbiology.

[47]  M. Barry,et al.  Comparison of adenovirus fiber, protein IX, and hexon capsomeres as scaffolds for vector purification and cell targeting. , 2006, Virology.

[48]  K. Mansfield,et al.  Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity , 2006, Nature.

[49]  B. Walker,et al.  Neutralizing Antibodies to Adenovirus Serotype 5 Vaccine Vectors Are Directed Primarily against the Adenovirus Hexon Protein1 , 2005, The Journal of Immunology.

[50]  T. Richmond,et al.  Baculovirus expression system for heterologous multiprotein complexes , 2004, Nature Biotechnology.

[51]  Y. Mikyas,et al.  Postentry Neutralization of Adenovirus Type 5 by an Antihexon Antibody , 2004, Journal of Virology.

[52]  A. Wlodawer,et al.  Kinetic stability and crystal structure of the viral capsid protein SHP. , 2004, Journal of molecular biology.

[53]  Andreas Plückthun,et al.  Stability improvement of antibodies for extracellular and intracellular applications: CDR grafting to stable frameworks and structure-based framework engineering. , 2004, Methods.

[54]  D. Curiel,et al.  Transductional targeting of adenoviral cancer gene therapy. , 2004, Current gene therapy.

[55]  H. Mizuguchi,et al.  Reduction of Natural Adenovirus Tropism to Mouse Liverby Fiber-Shaft Exchange in Combination with both CAR- andαv Integrin-BindingAblation , 2003, Journal of Virology.

[56]  D. Palmer,et al.  Improved system for helper-dependent adenoviral vector production. , 2003, Molecular therapy : the journal of the American Society of Gene Therapy.

[57]  F. Nestle,et al.  The αvβ5 integrin of hematopoietic and nonhematopoietic cells is a transduction receptor of RGD-4C fiber-modified adenoviruses , 2003, Gene Therapy.

[58]  R. Burger,et al.  Complement activation by recombinant adenoviruses , 2001, Gene Therapy.

[59]  I. Kovesdi,et al.  Reducing the Native Tropism of Adenovirus Vectors Requires Removal of both CAR and Integrin Interactions , 2001, Journal of Virology.

[60]  R. Alemany,et al.  Blood clearance rates of adenovirus type 5 in mice. , 2000, The Journal of general virology.

[61]  W. Wold.  Adenovirus Methods and Protocols , 1998, Methods in Molecular Medicine™.

[62]  B. Davidson,et al.  Complexes of Adenovirus with Polycationic Polymers and Cationic Lipids Increase the Efficiency of Gene Transfer in Vitro and in Vivo* , 1997, The Journal of Biological Chemistry.

[63]  J. Bergelson,et al.  Isolation of a Common Receptor for Coxsackie B Viruses and Adenoviruses 2 and 5 , 1997, Science.

[64]  Ari Helenius,et al.  Stepwise dismantling of adenovirus 2 during entry into cells , 1993, Cell.

[65]  G. Nemerow,et al.  Integrins α v β 3 and α v β 5 promote adenovirus internalization but not virus attachment , 1993, Cell.

[66]  Susumu Tonegawa,et al.  RAG-1-deficient mice have no mature B and T lymphocytes , 1992, Cell.

[67]  S. Kochanek,et al.  Fully detargeted polyethylene glycol-coated adenovirus vectors are potent genetic vaccines and escape from pre-existing anti-adenovirus antibodies. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[68]  R. M. Burnett,et al.  Large-scale purification and crystallization of adenovirus hexon. , 2007, Methods in molecular medicine.

[69]  Claes WOHLFARTt.  Neutralization of Adenoviruses: Kinetics, Stoichiometry, and Mechanisms , 2022 .